基于常规实验室检查预测急性髓系白血病FLT3-ITD突变的机器学习模型开发与验证
该研究利用瑞金医院2021-2024年连续初诊AML患者数据,开发并验证基于常规实验室检查的机器学习模型以预测FLT3-ITD突变概率。训练队列254例、内部时间验证84例、外部验证176例(BeatAML2),梯度提升机模型表现最佳,三队列AUC分别为0.847、0.772和0.760,SHAP分析显示绝对原始细胞计数贡献最大。
要点
- 基于四项常规实验室特征构建的GBM模型可用于初诊AML的FLT3-ITD突变风险分层。
- 模型在训练、内部验证和外部验证队列的AUC分别为0.847、0.772和0.760。
- 绝对原始细胞计数是对模型贡献最大的特征。
核心结论
- 基于常规实验室检查的GBM模型有助于识别初诊AML中应优先进行FLT3-ITD快速分子检测的患者。
研究设计与样本
- 回顾性纳入瑞金医院2021-2024年连续初诊AML患者,2021-2023年诊断者为训练队列(n=254),2024年诊断者为内部时间验证队列(n=84),BeatAML2队列为外部验证(n=176),共514例。
主要发现
- Boruta算法筛选出五个候选特征并构建了简单的四特征模型。
- 梯度提升机模型在训练、内部验证和外部验证队列的AUC分别为0.847、0.772和0.760。
- SHAP分析显示绝对原始细胞计数对模型贡献最大。
临床怎么用
- 模型可部署为网页计算器,辅助临床在初诊AML中优先安排FLT3-ITD快速分子检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) mutations are clinically important in acute myeloid leukaemia (AML). We developed and validated a machine learning model using routine laboratory tests to estimate the probability of FLT3-ITD mutations in newly diagnosed AML to prioritise rapid molecular testing. Consecutive patients treated at Ruijin Hospital during 2021-2024 were included. Those diagnosed in 2021-2023 comprised the training cohort, and those in 2024 formed the internal temporal validation cohort, and the BeatAML2 cohort served as external validation. Following Boruta feature selection, seven machine learning algorithms were evaluated via area under the receiver operating characteristic curve (AUC). The optimal model was interpreted using SHapley Additive exPlanations (SHAP) and deployed as a web-based calculator. Overall, 514 patients were included (training, n = 254; validation, n = 84; external validation, n = 176). Boruta algorithm selected five candidate features, and a simple four-feature model was constructed. Gradient boosting machine (GBM) performed best, with AUCs of 0.847, 0.772 and 0.760 in the training, internal validation and external validation cohorts respectively. SHAP analysis showed absolute blast count contributed most to the model. The GBM model may help identify patients with newly diagnosed AML who should be prioritised for rapid molecular testing for FLT3-ITD mutations.
引用
- Song J, Gu Z, Han J, et al. Development and validation of a machine learning model based on routine laboratory tests for predicting FLT3-ITD mutations in acute myeloid leukaemia. Br J Haematol. 2026. PMID: 42686039. doi:10.1111/bjh.70829
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。